Promentis Pharmaceuticals focuses on developing antipsychotic drugs to treat schizophrenia. Founded by David A. Baker and John Mantsch in 2006, Promentis Pharmaceuticals is backed by investors that include National Institutes of Health, F-Prime Capital, OrbiMed, Aisling Capital, and Black Horse Investments and is headquartered in Milwaukee.